Virtual Library

Start Your Search

Marco Marchisio



Author of

  • +

    P1 - Poster Viewing (ID 5)

    • Event: NACLC 2019
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 10/11/2019, 16:45 - 18:00, Exhibit Hall
    • +

      P1.09 - Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation in NSCLC (ID 89)

      16:45 - 18:00  |  Author(s): Marco Marchisio

      • Abstract

      Background:
      The recent introduction of the concept of “precision medicine” in oncology pushed the scientific interest to focusing on the research of dynamic measurable biomarkers that could lead to better predict response to novel anticancer therapies and improve clinical outcomes. Recently, it has been described the involvement of Extracellular Vesicles (EVs) in cancer pathophysiology and, given that EVs are released from all cell types under specific stimuli, they have been also proposed as potential biomarkers in cancer. Very few studies have expolred the potential diagnostic or prognostic function of EVs in NSCLC and none of them have focused on the role of cancer-stem derived EVs.


      Method:
      We have applied a novel and simplified polychromatic flow cytometry method to a cohort of metastatic and locally advanced NSCLC cancer patients (n= 51), which were further matched with gender- and age-matched healthy volunteers (n=25). A spectrum of cancer-related (CD133, CD326, CD90, CD29), endothelial (CD31) and leukocyte (CD45) markers was used to analyze differences in terms of blood circulating EV phenotypes between NSCLC patients and healthy volunteers, as well as they were correlated to clinical outcomes. Finally, EVs from patients and controls were isolated by instrumental cell sorting and their protein cargoes were analyzed by proteomics.


      Results:
      Results demonstrated that EV counts were significantly higher in NSCLC cancer patients than in healthy volunteers (9600 EVs/?l CI 95% 3867-75021 vs 5207 EVs/?l CI 95 % 1751-13531 p-value 0.0001). More interestingly, results also demonstrated that NSCLC patient groups presented significantly higher concentrations of circulating tumor cancer stem cell-derived CD133+CD326- EVs, when compared to healthy volunteers (151 EVs/?l CI 95% 4-3376 vs 34 EVs/?l CI 95 % 0-260 p-value 0.001) . Higher levels of CD133+CD326- (>148.5 EVs/?l) significantly correlated with a poor overall survival of the analyzed population (HR 2.60 CI 95% 1.26-5.37 p-value 0.01) . Additionally, proteomic analysis of EV cargoes demonstrated disparities in terms of protein content and function between circulating EVs in cancer patients and healthy controls.


      Conclusion:
      All in all, our data strongly suggest that blood circulating cancer stem cell-derived EVs may have a role as a diagnostic and prognostic biomarker in NSCLC.